Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Nature Medicine|September 25, 2025
Antibody-mediated LOX-1 inhibition in patients with residual inflammation after myocardial infarction: a randomized phase 2 trialMichelle L O'Donoghue, David A Morrow, Andrea L Vavere, et al.
Journal of the American College of Cardiology|February 18, 2022
Predictors of Left Main Coronary Artery Disease in the ISCHEMIA TrialRoxy Senior, Harmony R Reynolds, James K Min, et al.
The New England Journal of Medicine|February 8, 2019
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa InhibitorsStuart J Connolly, Mark Crowther, John W Eikelboom, et al.
Circulation. Genomic and Precision Medicine|February 9, 2021
Pharmacogenomics of the Efficacy and Safety of Colchicine in COLCOTMarie-Pierre Dubé, Marc-André Legault, Audrey Lemaçon, et al.
JAMA Cardiology|February 28, 2019
Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical TrialJudith S Hochman, Harmony R Reynolds, Sripal Bangalore, et al.
The New England Journal of Medicine|July 26, 2011
Apixaban with antiplatelet therapy after acute coronary syndromeJohn H Alexander, Renato D Lopes, Stefan James, et al.
Lancet (London, England)|November 9, 2015
Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trialA Michael Lincoff, Roxana Mehran, Thomas J Povsic, et al.
Annals of Internal Medicine|March 20, 2023
Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 HospitalizationTracy Y Wang, Abdus S Wahed, Alison Morris, et al.
European Journal of Heart Failure|March 28, 2017
New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessmentMartin R Cowie, Gerasimos S Filippatos, Maria de Los Angeles Alonso Garcia, et al.
The Lancet. Respiratory Medicine|May 30, 2021
Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trialJean-Claude Tardif, Nadia Bouabdallaoui, Philippe L L'Allier, et al.
Pageof 8